

THC BioMed Form 7

MONTHLY PROGRESS REPORT

October 2020

Name of CSE Issuer **THC BioMed Intl Ltd. ("THC BioMed")**
Trading Symbol: **THC**
Number of Outstanding Listed Securities **163,426,056 common shares and 48,921,971 reserved for Issuance**
Date: **December 2, 2020**

Report on Business

1. Provide a general overview and discussion of the development of the Issuer's business and operations over the previous month. Where the Issuer was inactive disclose this fact.

During the period, the Issuer announced that it had completed a second tranche of the private placement announced on October 22, 2020. The Issuer issued 3,636,363 units ("Units") at a price of \$0.11 per Unit, for total proceeds of \$399,999.93.

Each Unit consists of one common share and one common share purchase warrant. Each Unit warrant entitles the holder to purchase one common share of the Issuer for a period of 24 months from closing at a price of \$0.15 per share.

There was a commission of 7% cash and 7% broker warrants. The broker warrants have the same terms as the Unit warrants.

The proceeds raised through the private placements will be used for general working capital.

On November 13, THC provided a summary of the financial results for the fiscal year ended July 31, 2020:

- **Annual Revenue of \$4,178,179**
- **EBITDA (Earnings Before Interest Taxes, Depreciation, and Amortization) of \$1,167,003**
- **Revenue for the quarter increased 159% compared to the same period last year**
- **Delivered largest single sales order in the quarter ended July 31, 2020 of just over \$550,000**
- **Began shipment of cannabis beverage shot, THC Kiss, to the adult recreational cannabis market**
- **Filed for a U.S. trademark for the use of "THC Kiss" in the U.S. THC BioMed Ltd. owns the common-law rights and the trademark application for "THC Kiss" in Canada**
- **Began production of Pure Cannabis Sticks; however, delivery has been delayed due to supply chain issues as a result of the general slowdown caused by COVID-19**

“Sales in Q4 improved over sales in Q3 due to the quantity of product sold. The overall selling prices for cannabis in the retail market are lower, putting pressure on Licensed Producers to improve production efficiencies. Although the quarter ended July 31, 2020 resulted in a loss of \$642,989, for the year ended July 31, 2020, the net and comprehensive loss was \$161,590. Our focus now is on production of our cannabis beverage shot, THC Kiss, and our Pure Cannabis Sticks which will improve our gross margin,” said THC BioMed President & CEO, John Miller.

2. Provide a general overview and discussion of the activities of management.

Management continues to work on the conduct of the company’s business plan, growth and harvest of product, new product testing and expansion plans.

3. Describe and provide details of any new products or services developed or offered. For resource companies, provide details of new drilling, exploration or production programs and acquisitions of any new properties and attach any mineral or oil and gas or other reports required under Ontario securities law.

None.

4. Describe and provide details of any products or services that were discontinued. For resource companies, provide details of any drilling, exploration or production programs that have been amended or abandoned.

None.

5. Describe any new business relationships entered into between the Issuer, the Issuer’s affiliates or third parties including contracts to supply products or services, joint venture agreements and licensing agreements etc. State whether the relationship is with a Related Person of the Issuer and provide details of the relationship.

None.

6. Describe the expiry or termination of any contracts or agreements between the Issuer, the Issuer’s affiliates or third parties or cancellation of any financing arrangements that have been previously announced.

None.

7. Describe any acquisitions by the Issuer or dispositions of the Issuer’s assets that occurred during the preceding month. Provide details of the nature of the assets acquired or disposed of and provide details of the consideration paid or payable together with a schedule of payments if applicable, and of any valuation. State how the consideration was determined and whether the acquisition was from or the disposition was to a Related Person of the Issuer and provide details of the relationship.

None.

8. Describe the acquisition of new customers or loss of customers.

FORM 7 – MONTHLY PROGRESS REPORT

The Issuer has continued to register new patients.

9. Describe any new developments or effects on intangible products such as brand names, circulation lists, copyrights, franchises, licenses, patents, software, subscription lists and trademarks.

None.

10. Report on any employee hiring's, terminations or lay-offs with details of anticipated length of lay-offs.

None, except in the ordinary course of business.

11. Report on any labour disputes and resolutions of those disputes if applicable.

None.

12. Describe and provide details of legal proceedings to which the Issuer became a party, including the name of the court or agency, the date instituted, the principal parties to the proceedings, the nature of the claim, the amount claimed, if any, if the proceedings are being contested, and the present status of the proceedings.

None.

13. Provide details of any indebtedness incurred or repaid by the Issuer together with the terms of such indebtedness.

None.

14. Provide details of any securities issued and options or warrants granted.

Security	Number Issued	Details of Issuance	Use of Proceeds ⁽¹⁾
Units	3,636,363	Each Unit consists of one common share (a "Common Share") and one commons share purchase warrant (a "Warrant"). Each Warrant entitles the holder to purchase one Common Share of the Issuer for a period of 24 months from closing at a price of \$0.15 per share.	\$399,999.93 – The Issuer intends to use the proceeds for general working capital
Warrants	254,545	Each Warrant entitles the holder to purchase	Not applicable

		one Common Share of the Issuer for a period of 24 months from closing at a price of \$0.15 per share.	
--	--	---	--

(1) State aggregate proceeds and intended allocation of proceeds.

15. Provide details of any loans to or by Related Persons.

None.

16. Provide details of any changes in directors, officers or committee members.

None.

17. Discuss any trends which are likely to impact the Issuer including trends in the Issuer's market(s) or political/regulatory trends.

The Issuer's business involves certain risks and uncertainties that are inherent to the Issuer's industry. For disclosure on risks related to an investment in the Issuer, please refer to the Issuer's most recent Management's Discussion and Analysis under the titles "Financial Instruments and Risk Management" and "Other Risks and Uncertainties", which is available on SEDAR at www.sedar.com.

The outbreak of COVID-19 has significantly increased economic uncertainty. In addition, public and private sector policies and initiatives to reduce the transmission of COVID-19, such as the imposition of travel restrictions and the adoption of remote working, have impacted our business and operations. COVID-19 is impacting our contractors' ability to provide services to us, including professional services such as accounting and auditing due to social distancing measures.

Certificate of Compliance

The undersigned hereby certifies that:

1. The undersigned is a director and senior officer of the Issuer and has been duly authorized by a resolution of the board of directors of the Issuer to sign this Certificate of Compliance.
2. As of the date hereof there is no material information concerning the Issuer which has not been publicly disclosed.
3. The undersigned hereby certifies to CSE that the Issuer is in compliance with the requirements of applicable securities legislation (as such term is defined in National Instrument 14-101) and all CSE Requirements (as defined in CSE Policy 1).
4. All of the information in this Form 7 Monthly Progress Report is true.

FORM 7 – MONTHLY PROGRESS REPORT



Dated: **December 2, 2020.**

John Miller

Name of Director or Senior Officer

“John Miller”

Signature

President and CEO

Official Capacity

Issuer Details		
Name of Issuer: THC BioMed Intl Ltd.	For Month End November	Date of Report: YYYYMMDD 2020/12/02
Issuer Address: P.O. Box 20033 Towne Centre		
City/Province/Postal Code: Kelowna, BC V1Y 9H2	Issuer Fax No.: N/A	Issuer Telephone No. (250) 870-2512
Contact Name: John Miller	Contact Position: President & CEO	Contact Telephone No. (250) 870-2512
Contact Email Address: info@thcbiomed.com	Web Site Address: www.thcbiomed.com	